SynthesisMolecules (Basel, Switzerland)2025
Graphene Quantum Dots for Glioblastoma Treatment and Detection-Systematic Review.
Synthesis in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Layers of Hope: How Graphene and Nanostructures Hold Promise for Cancer Therapy.International journal of molecular sciences · 2026Review
- Review
- Global trends and knowledge structure of graphene based cancer research between 2016 and 2025.Discover oncology · 2025Article
- Graphene quantum dot-integrated nanocomposites: a promising avenue for glioblastoma treatment.Medical oncology (Northwood, London, England) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma, a highly malignant tumor, has a poor prognosis, necessitating the development of effective therapeutic strategies due to the low success rates of existing treatments. Graphene quantum dots (GQDs) have garnered attention for their unique physicochemical, electronic, and optical properties, along with biocompatibility and the ability to cross the blood-brain barrier. This systematic review evaluates the current applications of GQDs in glioblastoma management. A search across databases such as PubMed, Science Direct, and Web of Science identified 658 papers, with 10 selected for this review based on the eligibility criteria. Most of the selected studies explored GQDs as pretreatment agents for therapies like chemotherapy and photothermal therapy, alongside their roles in biosensing, bioimaging, and drug delivery. Although research is still limited, this review highlights the significant potential of GQDs as multifunctional platforms in glioblastoma therapy. Further studies are essential to optimize these nanostructures for clinical applications, aiming to improve the precision and effectiveness of treatments while reducing systemic side effects.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.